Agilon Health (AGL) Q3 2024: Exits 10% of Payer Contracts, Resets Margin Baseline for 2025

2024-11-07 | By EarningsIQ Research

Agilon Health’s Q3 2024 call marks a decisive reset, with management exiting unprofitable partnerships and 10% of payer contracts to restore margin discipline and stem cash burn. While core Medicare Advantage (MA) membership growth remains robust, medical margin underperformance and risk adjustment volatility triggered a comprehensive repricing and operational overhaul. Investors should watch for execution on data, risk mitigation, and contract economics as Agilon pivots toward a 2025 inflection point.

Summary

• Margin Reset Through Exits: Agilon is exiting two partnerships and 10% of payer contracts to improve profitability and reduce risk exposure.
• Data and Risk Adjustment Gaps: Management identified execution lapses in risk adjustment, driving renewed focus on data integration and payer collaboration.
• 2025 as Inflection Year: Strategic actions aim to create a stronger foundation for 2025, with a focus on sustainable cash flow and margin improvement.

Business Overview

Agilon Health operates a value-based care platform focused on enabling primary care physicians to manage full-risk Medicare Advantage (MA) and Accountable Care Organization (ACO) populations. The company’s model partners with physician groups and payers, taking on clinical and financial risk in exchange for a share of premiums, with performance tied to cost management and quality metrics. Major segments include MA partnerships (the bulk of revenue and membership) and ACO REACH entities (Medicare fee-for-service risk-sharing arrangements).

Performance Analysis

Q3 2024 results reflect both the strengths and acute pain points of Agilon’s business model. MA membership grew 37% year-over-year to 525,000, with revenue up 28% to $1.45 billion. However, medical margin swung to a loss of $58 million, pressured by negative risk adjustment settlements, prior period development, and higher-than-expected medical utilization. Adjusted EBITDA turned negative $96 million, a sharp reversal from the prior year’s profitability.

Medical cost trend volatility and risk adjustment shortfalls were the primary drivers of underperformance. Management cited $65 million in lower risk adjustment revenue and $60 million in adverse prior period development, largely tied to Part D and risk adjustment finalization. Medical expense inflation, especially in Q2 and Q3, outpaced premium growth, prompting a downward revision to full-year margin and EBITDA guidance. Platform support costs remained stable at 3% of revenue, while geography entry costs dropped 60% year-over-year due to disciplined expansion and delayed market entries.

• Membership Growth Outpaces Margin: Robust MA member growth did not translate to medical margin, with core profitability impaired by external and executional factors.
• Cash Burn and Balance Sheet: Cash usage guidance increased to $165 million for 2024, with year-end cash projected at $365 million, reflecting operational headwinds and settlement timing.
• ACO REACH Stability: ACO model entities delivered $12 million adjusted EBITDA, down from $18 million, but remain a relative bright spot versus MA volatility.

Agilon’s financial reset is anchored in a deliberate narrowing of its partnership and payer base, with the goal of stabilizing earnings and restoring investor confidence in the path to profitability.

Executive Commentary

Strategic Positioning

1. Partnership and Payer Rationalization

Agilon is exiting two underperforming partnerships and approximately 10% of payer contracts, removing 45,000 to 75,000 members and up to $785 million in annualized revenue. This move is intended to eliminate persistent EBITDA losses and focus resources on markets and contracts with a clearer path to profitability. Management emphasized close collaboration with physician partners in making these decisions, signaling a prioritization of network health over scale for its own sake.

2. Risk Adjustment and Data Execution

Risk adjustment revenue gaps and Part D volatility have exposed operational weaknesses in data capture and payer integration. Leadership is doubling down on closing these execution gaps by enhancing data pipelines, improving burden of illness (BOI) assessment, and requiring more timely, granular data from payers. More than 85% of members are now in the financial data pipeline, with near real-time inpatient census data for 80% of the base—a marked improvement in visibility.

3. Contract Repricing and Quality Incentives

Repricing covers 40% of MA membership for 2025 renewals, with improved economics and increased upside tied to quality performance (notably STARS ratings). Over 50% of 2025 membership will have mitigated Part D risk exposure via carve-outs or corridors, reducing volatility. Alternative risk terms for new partners—including care management fees and phased risk assumption—introduce downside protection and support more sustainable onboarding.

4. Tightening Physician Engagement and Panel Management

Active panel management reviews and expanded regional medical director teams are being scaled to over 20 markets, aiming to drive better cost control, quality scores, and accurate condition coding. Management sees these operational levers as key to closing the gap between membership growth and medical margin realization.

5. Cash Flow and Capital Discipline

With cash burn guidance increased and break-even cash flow now targeted for 2027, Agilon is emphasizing cost control, delayed market entries, and selective partnership expansion. The company’s $365 million cash position is viewed as sufficient for the current strategy, but execution risk remains if margin recovery lags.

Key Considerations

This quarter’s reset reflects both the strengths and vulnerabilities of Agilon’s value-based care model. The actions taken are designed to realign the business with its core profitability thesis while addressing execution and market risk.

Key Considerations:

• Margin Recovery Hinges on Execution: Sustained improvement depends on closing the risk adjustment and Part D data gaps, as well as realizing the benefits from contract repricing and partnership exits.
• Data Visibility as a Strategic Lever: Enhanced payer data pipelines and leading indicator tracking are critical to forecasting and managing medical cost trends.
• Quality Performance Drives Upside: STARS ratings and quality incentives are increasingly central to contract economics and payer relationships.
• Cash Burn and Capital Adequacy: While cash reserves are adequate for now, prolonged margin pressure could necessitate further cost actions or capital raises if improvement lags.

Risks

Execution risk remains high, particularly around timely risk adjustment capture, payer data exchange, and the ability to deliver margin lift from partnership exits and contract repricing. Regulatory changes (e.g., STARS cut points, physician fee schedule reductions) and ongoing medical cost inflation may further pressure margins and cash flow. If operational fixes and contract improvements do not materialize as planned, Agilon could face extended losses or need to revisit its capital plan.

Forward Outlook

For Q4 2024, Agilon guided to:

• MA membership of 527,000 (up from prior guidance)
• Full-year revenue midpoint of $6.057 billion (reflecting higher membership but lower risk adjustment)

For full-year 2024, management lowered guidance:

• Medical margin midpoint to $225 million (down from $400–450 million)
• Adjusted EBITDA to negative $135 million to negative $155 million

Management highlighted several factors that will shape 2025:

• Exiting unprofitable partnerships and payer contracts to improve baseline margin
• Repricing 40% of MA book and shifting more members to risk-mitigated Part D arrangements
• Continued investment in data infrastructure and BOI assessment to close execution gaps

Takeaways

Agilon’s Q3 reset is a necessary course correction for a value-based care platform navigating margin headwinds and operational complexity.

• Decisive Exits Signal Margin Discipline: The willingness to shed scale for profitability may set a precedent for other risk-bearing physician platforms facing similar pressures.
• Data and Execution Are Now Central: Margin recovery will depend on closing the loop between physician engagement, payer data integration, and risk adjustment capture.
• 2025 Will Test the Model: Investors should monitor how quickly Agilon can translate strategic actions into sustainable cash flow and margin improvement before capital constraints resurface.

Conclusion

Agilon’s Q3 2024 call marks a turning point, with leadership taking hard decisions to reset the business for a more sustainable future. The company’s ability to deliver on data, contracting, and operational execution will determine whether 2025 becomes the inflection year management is targeting.

Industry Read-Through

Agilon’s retrenchment underscores the operational and financial risks inherent in value-based care platforms scaling full-risk MA contracts. The need to exit unprofitable partnerships and renegotiate payer terms highlights the challenge of balancing growth with disciplined margin management. For other physician enablement and risk-bearing models, the quarter signals that data integration, risk adjustment accuracy, and payer collaboration are not optional but foundational. Expect broader scrutiny of risk corridor arrangements, data lags, and the sustainability of rapid membership growth without corresponding margin lift across the sector.

AGL Healthcare Managed Care Value-Based Care Medicare Advantage Risk Adjustment Part D Membership